Astellas, FibroGen Start Phase II Study – Analyst Blog
Astellas Pharma, Inc. ( ALPMY ) and FibroGen Inc., a privately held biotechnology company, recently commenced a phase II study …read more
Astellas Pharma, Inc. ( ALPMY ) and FibroGen Inc., a privately held biotechnology company, recently commenced a phase II study …read more
Leading player in the women’s health market Hologic Inc. ( HOLX ) recently gained the U.S. Food and Drug Administration …read more
Retail shares have been hot performers in 2013. The SPDR S&P 500 Retail ETF ( XRT ) was up over …read more
Watts Water Technologies, Inc. ( WTS ) has completed the sale of all outstanding shares of an indirect wholly owned …read more
Shares of the meat processor Tyson Foods Inc. ( TSN ) reached a new 52 week high of $29.85 on …read more
Experienced long term investors and traders have learned it doesn’t pay to give much weight to every market wiggle caused …read more
On Jul 31, we upgraded staffing & outsourcing company ManpowerGroup Inc. ( MAN ) to Outperform based on its improved …read more
On Aug 2, we maintained a Neutral rating on the U.S. homebuilder, KB Home ( KBH ), following its solid …read more
Aegerion Pharmaceuticals, Inc. ( AEGR ) recently obtained regulatory approval in the EU for Lojuxta. Lojuxta gained approval for use …read more
Sempra Energy ( SRE ) is set to report second quarter 2013 results on Aug 6, 2013, before the earnings …read more